| |SEPTEMBER 20249PRISTYN CARE UNVEILS INNOVATION LAB TO DRIVE AI ADVANCEMENTSTITAN PHARMA FORAYS INTO MERGER AGREEMENT WITH KE SDN. BHD.Pristyn Care, a top player in follow-up surgeries in India, has launched the Innovation Lab, a specialized program aiming to foster progress in AI in the healthcare industry. It will offer AI startups in their early stages a special opportunity to test and improve their solutions in real healthcare settings. Out of the 47 startups that have submitted applications, only a few will be selected to collaborate, and their names will be revealed upon joining the lab. This project seeks to promote creativity and speed up the progress of revolutionary AI advancements in the medical field.Accessing anonymized patient data, operational workflows, and pilot programs in specific departments like patient interaction and insurance analysis would be available. It will deliver input from Pristyn Care's medical professionals, operational team, and tech experts, as well as compare performance to traditional methods in place."We are excited to partner with AI startups to drive a revolution in Indian healthcare. The adoption of AI is not just a trend but a crucial necessity for transforming the healthcare landscape in India. As the industry faces increasing demands for efficiency and improved patient outcomes, AI offers unparalleled opportunities for growth and innovation. The Innovation Lab is a testament to this commitment," said Harsimarbir Singh, co-founder Pristyn Care. POTitan Pharmaceuticals, Inc. has revealed that it is engaged in a Merger and Contribution and Share Exchange Agreement for a business merger with KE Sdn. Berhad. The board of directors of Titan approved the Merger Agreement. If Titan's and KE's stockholders approve the Merger Agreement and the transactions outlined in the agreement are completed, Titan will merge with KE in a "reverse merger" involving two steps.TTNP Merger Sub, Inc, a company based in Delaware and a fully owned subsidiary of BSKE Ltd, an exempted company in Cayman Islands, will merge with and into Titan; the separate entity of Merger Sub will end; and Titan will become the surviving company of the merger and a direct fully owned subsidiary of BSKE.Within five days of Titan and BSKE submitting a proxy statement/prospectus for the planned transaction, KE shareholders have the option to participate in a share exchange agreement with biopharmaceutical company and BSKE. This agreement will involve exchanging all KE shares for BSKE ordinary shares immediately after the Merger. Titan has the right to cancel the Merger Agreement if not all KE shareholders participate in the Share Exchange Agreement within the given timeframe. PO
< Page 8 | Page 10 >